{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:10:20Z","timestamp":1761156620181},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00393-018-0584-5","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T13:02:50Z","timestamp":1547730170000},"page":"221-227","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Kardiovaskul\u00e4re Komorbidit\u00e4ten bei rheumatoider Arthritis"],"prefix":"10.1007","volume":"78","author":[{"given":"K.","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"N\u00fc\u00dflein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"584_CR1","volume-title":"Kerndokumentation","author":"Deutsches Rheumaforschungszentrum","year":"2016","unstructured":"Deutsches Rheumaforschungszentrum (2016) Kerndokumentation. Deutsches Rheumaforschungszentrum, Berlin (Daten noch unpubliziert)"},{"key":"584_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acr.22642","volume":"68","author":"BR England","year":"2016","unstructured":"England BR, Sayles H, Michaud K et al (2016) Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res 68:36\u201345","journal-title":"Arthritis Care Res"},{"key":"584_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.rdc.2018.03.006","volume":"44","author":"RH Mackey","year":"2018","unstructured":"Mackey RH, Kuller LH, Moreland LW (2018) Update on cardiovascular disease risk in patients with rheumatic diseases. Rheum Dis Clin North Am 44:475\u2013487","journal-title":"Rheum Dis Clin North Am"},{"key":"584_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","volume":"11","author":"S Skeoch","year":"2015","unstructured":"Skeoch S, Bruce IN (2015) Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 11:390\u2013400","journal-title":"Nat Rev Rheumatol"},{"key":"584_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM (2016) From C\u2011reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118:145\u2013156","journal-title":"Circ Res"},{"issue":"52","key":"584_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/art.20853","volume":"2005","author":"H Maradit-Kremers","year":"2005","unstructured":"Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005(52):402\u2013411","journal-title":"Arthritis Rheum"},{"key":"584_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2013-203617","volume":"73","author":"GA Karpouzas","year":"2014","unstructured":"Karpouzas GA, Malpeso J, Choi TY et\u00a0al (2014) Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 73:1797\u20131804","journal-title":"Ann Rheum Dis"},{"key":"584_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2796.2010.02260.x","volume":"268","author":"ME Holmqvist","year":"2010","unstructured":"Holmqvist ME, Wedren S, Jacobsson LTH et\u00a0al (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J\u00a0Intern Med 268:578\u2013585","journal-title":"J Intern Med"},{"key":"584_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","volume":"77","author":"CS Crowson","year":"2018","unstructured":"Crowson CS, Rollefstad S, Ikdahl E et\u00a0al (2018) Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 77:48\u201354","journal-title":"Ann Rheum Dis"},{"key":"584_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","volume":"76","author":"EEA Arts","year":"2017","unstructured":"Arts EEA, Fransen J, Den Broeder AA et al (2017) Low disease activity (DAS28\u22643.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a\u00a0large cohort study. Ann Rheum Dis 76:1693\u20131699","journal-title":"Ann Rheum Dis"},{"key":"584_CR11","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM et\u00a0al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum 67:1449\u20131455","journal-title":"Arthritis Rheum"},{"key":"584_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.semarthrit.2011.07.004","volume":"41","author":"CP Chung","year":"2012","unstructured":"Chung CP, Giles JT, Petri M et al (2012) Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 41:535\u2013544","journal-title":"Semin Arthritis Rheum"},{"key":"584_CR13","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2013-203682","volume":"72","author":"J Primdahl","year":"2013","unstructured":"Primdahl J, Clausen J, H\u00f8rslev-Petersen K (2013) Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis 72:1771\u20131776","journal-title":"Ann Rheum Dis"},{"key":"584_CR14","first-page":"1789","volume":"57","author":"TJ Schmidt","year":"2018","unstructured":"Schmidt TJ, Avina-Zubieta JA, Sayre EC et al (2018) Quality of care for cardiovascular disease prevention in rheumatoid arthritis: compliance with hyperlipidemia screening guidelines. Baillieres Clin Rheumatol 57:1789\u20131794","journal-title":"Baillieres Clin Rheumatol"},{"key":"584_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3899\/jrheum.170973","volume":"45","author":"TJ Schmidt","year":"2018","unstructured":"Schmidt TJ, Avina-Zubieta JA, Sayre EC et al (2018) Cardiovascular\u00a0disease prevention in rheumatoid arthritis: compliance with diabetes screening guidelines. J\u00a0Rheumatol 45:1367\u20131374","journal-title":"J Rheumatol"},{"key":"584_CR16","first-page":"1472","volume":"56","author":"IAM Oever Van den","year":"2017","unstructured":"Van den Oever IAM, Heslinga M, Griep EN et\u00a0al (2017) Cardiovascular risk management in\u00a0rheumatoid arthritis\u00a0patients still suboptimal: the implementation of cardiovascular risk management in\u00a0rheumatoid arthritis\u00a0project. Baillieres Clin Rheumatol 56:1472\u20131478","journal-title":"Baillieres Clin Rheumatol"},{"key":"584_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3899\/jrheum.160110","volume":"43","author":"JJ An","year":"2016","unstructured":"An JJ, Alemao E, Reynolds K et al (2016) Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis. J\u00a0Rheumatol 43:1989\u20131996","journal-title":"J Rheumatol"},{"key":"584_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2017.11.009","volume":"253","author":"CY Huang","year":"2018","unstructured":"Huang CY, Lin TT, Yang YH et al (2018) Effect of statin therapy on the prevention of new-onset acute coronary syndrome in patients with\u00a0rheumatoid arthritis. Int J Cardiol 253:1\u20136","journal-title":"Int J Cardiol"},{"key":"584_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00108-018-0397-2","volume":"59","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K (2018) Medikament\u00f6se Therapie der rheumatoiden Arthritis und ihrer Komorbidit\u00e4ten. Internist 59:341\u2013351","journal-title":"Internist"},{"key":"584_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23611","author":"JC Wilson","year":"2018","unstructured":"Wilson JC, Sarsour K, Gale S et al (2018) Incidence and risk of glucocorticoid-associated adverse effects in patients with\u00a0rheumatoid arthritis. Arthritis Care Res. \n                    https:\/\/doi.org\/10.1002\/acr.23611","journal-title":"Arthritis Care Res"},{"key":"584_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richter V, Starnino T et al (2015) The effects of tumour necrosis factor inhibitors,methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 74:480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"584_CR22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, Wyler von Ballmoos M et al (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362\u20131370","journal-title":"Am J Cardiol"},{"key":"584_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T et al (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 77:98\u2013103","journal-title":"Ann. Rheum. Dis."},{"key":"584_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"ASL Low","year":"2017","unstructured":"Low ASL, Symmons DPM, Lunt M et\u00a0al (2017) Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 76:654\u2013660","journal-title":"Ann Rheum Dis"},{"key":"584_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13075-018-1669-x","volume":"20","author":"JL Lee","year":"2018","unstructured":"Lee JL, Sinnathurai P, Buchbinder R et\u00a0al (2018) Biologics and cardiovascular events in inflammatory arthritis: a\u00a0prospective national cohort study. Arthritis Res Ther 20:171","journal-title":"Arthritis Res Ther"},{"key":"584_CR26","doi-asserted-by":"publisher","first-page":"e007393","DOI":"10.1161\/JAHA.117.007393","volume":"7","author":"EH Kang","year":"2018","unstructured":"Kang EH, Jin Y, Brill G et\u00a0al (2018) Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a Multidatabase cohort study. J\u00a0Am Heart Assoc 7:e7393. \n                    https:\/\/doi.org\/10.1161\/JAHA.117.007393","journal-title":"J Am Heart Assoc"},{"key":"584_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.03.012","author":"SC Kim","year":"2018","unstructured":"Kim SC, Solomon DH, Rogers JR et al (2018) No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.012","journal-title":"Semin Arthritis Rheum"},{"key":"584_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/STROKEAHA.115.012052","volume":"47","author":"SJ Wiseman","year":"2016","unstructured":"Wiseman SJ, Ralston SH, Wardlaw JM (2016) Cerebrovascular disease in rheumatic diseases. A systematic review and meta-analysis. Stroke 47:943\u2013950","journal-title":"Stroke"},{"key":"584_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000481992","volume":"49","author":"S Tiosano","year":"2017","unstructured":"Tiosano S, Yavne Y, Gendelman O et al (2017) Stroke among rheumatoid arthritis patients: does age matter? A real-life study. Neuroepidemiology 49:99\u2013105","journal-title":"Neuroepidemiology"},{"key":"584_CR30","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2017-211209","volume":"76","author":"Y Meissner","year":"2017","unstructured":"Meissner Y, Richter A, Manger B et\u00a0al (2017) Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis 76:1583\u20131590","journal-title":"Ann Rheum Dis"},{"key":"584_CR31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1007\/s00415-018-8885-9","volume":"265","author":"YR Chen","year":"2018","unstructured":"Chen YR, Hsieh FI, Lien LM et\u00a0al (2018) Rheumatoid arthritis significantly increased recurrence risk after ischemic stroke\/transient ischemic attack. J\u00a0Neurol 265:1810\u20131818","journal-title":"J Neurol"},{"key":"584_CR32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","volume":"41","author":"IC Scott","year":"2018","unstructured":"Scott IC, Hider SL, Scott DL (2018) Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Saf 41:645\u2013653","journal-title":"Drug Saf"},{"key":"584_CR33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/annrheumdis-2013-204767","volume":"73","author":"IAM Oever Van den","year":"2014","unstructured":"Van den Oever IAM, Sattar N, Nurmohamed MT (2014) Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 73:954\u2013957","journal-title":"Ann Rheum Dis"},{"key":"584_CR34","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/keu408","volume":"54","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, Srivali N, Wijarnpreecha K et al (2015) Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a\u00a0systematic review and meta-analysis. Rheumatology 54:736\u2013742","journal-title":"Rheumatology"},{"key":"584_CR35","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1136\/ard.2011.153536","volume":"70","author":"R Davies","year":"2011","unstructured":"Davies R, Galloway JB, Watson KD et al (2011) Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:1831\u20131834","journal-title":"Ann Rheum Dis"},{"key":"584_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","volume":"41","author":"A Verden","year":"2018","unstructured":"Verden A, Dimbil M, Kyle R et\u00a0al (2018) Analysis of spontaneous postmarket case reports submitted to the FDA regarding\u00a0thromboembolic\u00a0adverse events and JAK inhibitors. Drug Saf 41:357\u2013361","journal-title":"Drug. Saf."},{"key":"584_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.20855","volume":"52","author":"PJ Nicola","year":"2005","unstructured":"Nicola PJ, Maradit-Kremers H, Roger VL et al (2005) The risk of congestive heart failure in rheumatoid arthritis. A population-based study over 46 years. Arthritis Rheum 52:412\u2013420","journal-title":"Arthritis Rheum"},{"key":"584_CR38","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3899\/jrheum.141647","volume":"42","author":"T Schau","year":"2015","unstructured":"Schau T, Gottwald M, Arbach O et\u00a0al (2015) Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J\u00a0Rheumatol 42:2029\u20132037","journal-title":"J Rheumatol"},{"key":"584_CR39","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a\u00a0chimeric Monoclonal antibody to tumor necrosis factor-alpha in patients with moderate-to-severe heart failure. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"key":"584_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.23281","volume":"58","author":"J Listing","year":"2008","unstructured":"Listing J, Strangfeld A, Kekow J et al (2008) Does tumor necrosis factor alpha- inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667\u2013677","journal-title":"Arthritis Rheum"},{"key":"584_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/14712598.2018.1462794","volume":"18","author":"M Baniaamam","year":"2018","unstructured":"Baniaamam M, Paulus WJ, Blanken AB, Nurmohamed MT (2018) The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a\u00a0systematic review. Expert Opin Biol Ther 18:585\u2013594","journal-title":"Expert Opin Biol Ther"},{"key":"584_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.1268","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, Eder R, Mueller C, Rietzler K (2018) Assessing the risk of RA patients for comorbid conditions through a\u00a0structured nurse-led interview \u2013 the ERIKO study. Ann Rheum Dis. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.1268","journal-title":"Ann Rheum Dis"},{"key":"584_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollestad S et\u00a0al (2017) EULAR recommendations for cardiovascular\u00a0disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328","journal-title":"Ann Rheum Dis"},{"key":"584_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/03009742.2017.1337924","volume":"47","author":"M Breunig","year":"2018","unstructured":"Breunig M, Kleinert S, Lehmann S et\u00a0al (2018) Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol 47:102\u2013109","journal-title":"Scand J Rheumatol"},{"key":"584_CR45","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/rheumatology\/key057","volume":"57","author":"GA Karpouzas","year":"2018","unstructured":"Karpouzas GA, Estis J, Rezaeian P et al (2018) High-sensitivitycardiac\u00a0troponin\u00a0I is a\u00a0biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis. Rheumatology 57:1080\u20131088","journal-title":"Rheumatology"},{"key":"584_CR46","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/annrheumdis-2016-209744","volume":"76","author":"GJ Fent","year":"2017","unstructured":"Fent GJ, Greenwood JP, Plein S, Buch MH (2017) The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be. Ann Rheum Dis 76:1169\u20131175","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0584-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0584-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0584-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:04:48Z","timestamp":1579219488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0584-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0584-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"17 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Kr\u00fcger hat Honorare f\u00fcr Fortbildung\/Beratung von folgenden Firmen erhalten: AbbVie, BMS, Biogen, Hexal, Lilly, Medac, MSD, Novartis, Pfizer, Roche, UCB. H.\u00a0N\u00fc\u00dflein hat Honorare f\u00fcr Beratung und Vortr\u00e4ge von AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, UCB erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}